CD24 and non-small cell lung carcinoma: Furthermore, Ozawa et al. demonstrated that CD24 was a candidate negative predictive marker of immune-checkpoint inhibitors (ICI) in advanced, non-small-cell lung cancer (NSCLC) with PD-L1 TPS < 50 [111], which suggested that expression of CD24 was associated with changes in factors related to monocytes and angiogenesis after ICI initiation.